Gauss Surgical provides Triton, a platform that measures surgical blood loss in real time on the iPad using digital imaging and machine learning. The company has received de novo approval from the U.S. Food and Drug Administration and a European CE mark for the device. Triton has been adopted by 50 hospitals that together perform more than 200,000 infant deliveries each year. Gauss plans to use new funding to accelerate Triton adoption in hospitals and to develop additional AI-driven applications for the operating room. The company is led by founder and CEO Siddarth Satish and is based in Los Altos, California. Its recent financing improves its runway to scale clinical deployment and product development. Gauss Surgical developed Triton, a real-time platform for monitoring surgical blood loss that combines computer vision and machine learning. Triton supplies clinicians with accurate blood loss assessments to support surgical decision-making. The platform holds four FDA clearances and has received CE Mark approval. Triton is in clinical use at several U.S. health systems including HackensackUMC, Cedars-Sinai Medical Center, the MemorialCare Health System, and UC Irvine Medical Center. The company is led by founder and CEO Siddarth Satish and recently closed a $12.6M Series B. Gauss has raised $24.6M in total funding to date. Gauss Surgical develops a digital health app that quantifies surgical blood loss by measuring blood collected in canisters. The app received FDA 510(k) clearance a few months before the latest fundraise. Management says the tool can help reduce clinical and staff burnout by automating blood-loss measurement. Target use cases called out include obstetrics, patients with severe burns, and procedures prone to heavy blood loss such as orthopedic, cardiovascular, and pediatric surgery. The company has seen rising interest from prospective corporate and strategic investors exploring digital health solutions for hospitals. Gauss plans to use new funding to support sales and marketing for the app rollout.

Total raised

$45M

Funding rounds

3

Latest round

Series C

Latest activity

Oct 2018